Diverse compounds from pleuromutilin lead to a thioredoxin inhibitor and inducer of ferroptosis

Nature Chemistry

Volumn 11, Issue 6, 2019, Pages 521-532

  Llabani, Evijola ^a   Hicklin, Robert W ^a   Lee, Hyang Yeon ^a   Motika, Stephen E ^a   Crawford, Lisa A ^b   Weerapana, Eranthie ^b   Hergenrother, Paul J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b BOSTON COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZULENE DERIVATIVE; CYSTEINE; DITERPENE; IMMUNOLOGIC FACTOR; PLEUROMUTILIN; PYRIDAZINE DERIVATIVE; THIOREDOXIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL DEATH; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; LIPID PEROXIDATION; SCID MOUSE; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; AZULENES; CELL DEATH; CELL LINE, TUMOR; CYSTEINE; DITERPENES; HUMANS; IMMUNOLOGIC FACTORS; LIPID PEROXIDATION; MICE, INBRED BALB C; MICE, SCID; MOLECULAR STRUCTURE; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP; THIOREDOXINS;

EID: 85065757498     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/s41557-019-0261-6     Document Type: Article

References (64)

1. Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752–6756 (2009).
2. Swinney, D. C. & Anthony, J. How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507–519 (2011).
3. Galloway, W. R. J. D., Isidro-Llobet, A. & Spring, D. R. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat. Commun. 1, 80–93 (2010).
4. Gerry, C. J. & Schreiber, S. L. Chemical probes and drug leads from advances in synthetic planning and methodology. Nat. Rev. Drug Discov. 17, 333–352 (2018).
5. Morrison, K. C. & Hergenrother, P. J. Natural products as starting points for the synthesis of complex and diverse compounds. Nat. Prod. Rep. 31, 6–14 (2014).
6. Huigens, R. W. III et al. A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. Nat. Chem. 5, 195–202 (2013).
7. Ciardiello, J. J. et al. A novel complexity-to-diversity strategy for the diversity-oriented synthesis of structurally diverse and complex macrocycles from quinine. Bioorg. Med. Chem. 25, 2825–2843 (2017).
8. Rafferty, R. J., Hicklin, R. W., Maloof, K. A. & Hergenrother, P. J. Synthesis of complex and diverse compounds through ring distortion of abietic acid. Angew. Chem. Int. Ed. 53, 220–224 (2014).
9. Garcia, A., Drown, B. S. & Hergenrother, P. J. Access to a structurally complex compound collection via ring distortion of the alkaloid sinomenine. Org. Lett. 18, 4852–4855 (2016).
10. Tasker, S. Z., Cowfer, A. E. & Hergenrother, P. J. Preparation of structurally diverse compounds from the natural product lycorine. Org. Lett. 20, 5894–5898 (2018).
11. Paciaroni, N. G. et al. A tryptoline ring‐distortion strategy leads to complex and diverse biologically active molecules from the indole alkaloid yohimbine. Chem. Eur. J. 23, 4327–4335 (2017).
12. Govindaraju, K. et al. Novel topologically complex scaffold derived from alkaloid haemanthamine. Molecules 23, 255–263 (2018).
13. Charaschanya, M. & Aubé, J. Reagent-controlled regiodivergent ring expansions of steroids. Nat. Commun. 9, 934–942 (2018).
14. Laurent, E. et al. A ring‐distortion strategy from marine natural product ilimaquinone leads to quorum sensing modulators. Eur. J. Org. Chem. 2018, 2486–2497 (2018).
15. Xu, H. et al. Identification of a diverse synthetic abietane diterpenoid library for anticancer activity. Bioorg. Med. Chem. Lett. 27, 505–510 (2017).
16. Luca, L. et al. Discovery of novel cinchona‐alkaloid‐inspired oxazatwistane autophagy inhibitors. Angew. Chem. Int. Ed. 56, 2145–2150 (2017).
17. Richter, M. F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299–304 (2017).
18. Poulsen, S. M., Karlsson, M., Johansson, L. B. & Vester, B. The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Mol. Microbiol. 41, 1091–1099 (2001).
19. Ma, X. et al. Directed C–H bond oxidation of (+)-pleuromutilin. J. Org. Chem. 83, 6843–6892 (2018).
20. Farney, E. P., Feng, S. S., Schäfers, F. & Reisman, S. E. Total synthesis of (+)-pleuromutilin. J. Am. Chem. Soc. 140, 1267–1270 (2018).
21. Murphy, S. K., Zeng, M. & Herzon, S. B. A modular and enantioselective synthesis of the pleuromutilin antibiotics. Science 356, 956–959 (2017).
22. Thirring, K. et al. 12-epi-pleuromutilins. US patent WO2015110481A1 (2015).
23. Gibbons, E. G. Total synthesis of (±)-pleuromutilin. J. Am. Chem. Soc. 104, 1767–1769 (1982).
24. Paquette, L. A., Wiedeman, P. E. & Bulman-Page, P. C. (+)-Pleuromutilin synthetic studies. Degradative and de novo acquisition of a levorotatory tricyclic lactone subunit. J. Org. Chem. 53, 1441–1450 (1988).
25. Liu, J., Lotesta, S. D. & Sorensen, E. J. A concise synthesis of the molecular framework of pleuromutilin. Chem. Commun. 47, 1500–1502 (2011).
26. Birch, A. J., Holzapfel, C. W. & Rickards, R. W. The structure and some aspects of the biosynthesis of pleuromutilin. Tetrahedron 22, 359–387 (1966).
27. Arigoni, D. Some studies in the biosynthesis of terpenes and related compounds. Pure Appl. Chem. 17, 331–348 (1968).
28. Drews, J. et al. Antimicrobial activities of 81.723 hfu, a new pleuromutilin derivative. Antimicrob. Agents Chemother. 7, 507–516 (1975).
29. Yang, L. P. & Keam, S. J. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 68, 855–873 (2008).
30. Berner, H., Schulz, G. & Schneider, H. Synthese ab-trans-anellierter derivate des tricyclischen diterpens pleuromutilin durch intramolekulare 1,5-hydrid-verschiebung. Tetrahedron 36, 1807–1811 (1980).
31. Andemichael, Y. et al. Process development for a novel pleuromutilin-derived antibiotic. Org. Process Res. Dev. 13, 729–738 (2009).
32. Uccello, D. P. et al. The synthesis of C-13 functionalized pleuromutilins via C–H amidation and subsequent novel rearrangement product. Tetrahedron Lett. 52, 4247–4251 (2011).
33. Hicklin, R. W., López Silva, T. L. & Hergenrother, P. J. Synthesis of bridged oxafenestranes from pleuromutilin. Angew. Chem. Int. Ed. 53, 9880–9883 (2014).
34. Botham, R. C. et al. Dual small-molecule targeting of procaspase-3 dramatically enhances zymogen activation and anticancer activity. J. Am. Chem. Soc. 136, 1312–1319 (2014).
35. Parkinson, E. I., Bair, J. S., Cismesia, M. & Hergenrother, P. J. Efficient NQO1 substrates are potent and selective anticancer agents. ACS Chem. Biol. 8, 2173–2183 (2013).
36. Palchaudhuri, R. et al. A small molecule that induces intrinsic pathway apoptosis with unparalleled speed. Cell Rep. 13, 2027–2036 (2015).
37. Linkermann, A., Stockwell, B. R., Krautwald, S. & Anders, H.-J. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat. Rev. Immunol. 14, 759–767 (2014).
38. Galluzzi, L., Senovilla, L., Zitvogel, L. & Kroemer, G. The secret ally: immunostimulation by anticancer drugs. Nat. Rev. Drug Discov. 11, 215–233 (2012).
39. Lee, H. Y. et al. Reactive oxygen species synergize to potently and selectively induce cancer cell death. ACS Chem. Biol. 12, 1416–1424 (2017).
40. Stockwell, B. R. et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology and disease. Cell 171, 273–285 (2017).
41. Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060–1072 (2012).
42. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).
43. Shimada, K. et al. Global survey of cell death mechanisms reveals metabolic regulation of ferroptosis. Nat. Chem. Biol. 12, 497–503 (2016).
44. 2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat. Chem. Biol. 14, 507–515 (2018).
45. Lewerenz, J. et al. Oxytosis/ferroptosis—(re-)emerging roles for oxidative stress-dependent non-apoptotic cell death in diseases of the central nervous system. Front. Neurosci. 12, 214 (2018).
46. Murphy, T. H. et al. Calcium-dependent glutamate cytotoxicity in a neuronal cell line. Brain Res. 444, 325–332 (1988).
47. Miyamoto, M., Murphy, T. H., Schnaar, R. L. & Coyle, J. T. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line. J. Pharmacol. Exp. Ther. 250, 1132–1140 (1989).
48. Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metabol. 8, 237–248 (2008).
49. Yang, W. S. & Stockwell, B. R. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol. 15, 234–245 (2008).
50. Subramanian, A. et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171, 1437–1452 (2017).
51. Dixon, S. J. et al. Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis. eLife 3, e02523 (2014).
52. Banerjee, R., Pace, N. J., Brown, D. R. & Weerapana, E. 1,3,5-Triazine as a modular scaffold for covalent inhibitors with streamlined target identification. J. Am. Chem. Soc. 135, 2497–2500 (2013).
53. Holmgren, A. Thioredoxin structure and mechanism: conformational changes on oxidation of the active-site sulfhydryls to a disulfide. Structure 3, 239–243 (1995).
54. Nordberg, J. & Arnér, E. S. J. Reactive oxygen species, antioxidants and the mammalian thioredoxin system. Free Radic. Biol. Med. 31, 1287–1312 (2001).
55. Mukherjee, A. et al. A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines. Br. J. Pharmacol. 151, 1167–1175 (2007).
56. Baker, A. F. et al. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J. Lab. Clin. Med. 147, 83–90 (2006).
57. Kirkpatrick, D. L. et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides. Biochem. Pharmacol. 55, 987–994 (1998).
58. Sexton, D. W. Targeting airway inflammation: PMX464 and the epithelial bulls eye. Br. J. Pharmacol. 155, 620–622 (2008).
59. Reynoso, E. et al. Thioredoxin-1 actively maintains the pseudokinase MLKL in a reduced state to suppress disulfide bond-dependent MLKL polymer formation and necroptosis. J. Biol. Chem. 292, 17514–17524 (2017).
60. You, B. R., Shin, H. R. & Park, W. H. PX-12 inhibits the growth of A549 lung cancer cells via G2/M phase arrest and ROS-dependent apoptosis. Int. J. Oncol. 44, 301–308 (2014).
61. Li, Y., Qian, L. & Yuan, J. Small molecule probes for cellular death machines. Curr. Opin. Chem. Biol. 39, 74–82 (2017).
62. Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. Cell Death Differ. 25, 486–541 (2018).
63. Mai, T. T. et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat. Chem. 9, 1025–1033 (2017).
64. Bruni, A. et al. Ferroptosis-inducing agents compromise in vitro human islet viability and function. Cell Death Dis. 9, 595–605 (2018).